Total 939 Paclitaxel
related US patents (from
US Patent & Trademark Office)
No. 1
- 100 / 101-200
/ 201 - 300 / 301
- 400 / 401 - 500
/ 501 - 600 / 601
- 700 / 701 - 800
/ 801
- 900 / 901 -939
/
No. 1 - 100 Paclitaxel Patents:
|
PAT. NO. |
|
Title |
1 |
6,515,151 |
|
Method
for the preparation of novel sidechain-bearing taxanes and
intermediates thereof |
2 |
6,515,017 |
|
Water
soluble paclitaxel derivatives |
3 |
6,515,016 |
|
Composition
and methods of paclitaxel for treating psoriasis |
4 |
6,515,009 |
|
Therapeutic
inhibitor of vascular smooth muscle cells |
5 |
6,515,004 |
|
N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide
inhibitors of cyclin dependent kinases |
6 |
6,514,983 |
|
Compounds,
methods and pharmaceutical compositions for treating neural or
cardiovascular tissue damage |
7 |
6,514,738 |
|
KinI-3
motor protein and methods for its use |
8 |
6,514,535 |
|
Bioadhesive
hydrogels with functionalized degradable crosslinks |
9 |
6,514,491 |
|
Hydrolytically
degradable carbamate derivatives of poly(ethylene glycol) |
10 |
6,514,193 |
|
Method
of administering a therapeutically active substance |
11 |
6,512,123 |
|
Tricyclic
alkylhydroxamate derivatives |
12 |
6,511,973 |
|
Lactam
inhibitors of FXa and method |
13 |
6,511,676 |
|
Therapy
for human cancers using cisplatin and other drugs or genes
encapsulated into liposomes |
14 |
6,509,491 |
|
Aminohydroxylation
of olefins in the presence of acetamide |
15 |
6,509,484 |
|
Synthesis
of taxol, taxol analogs and their intermediates with variable
a-ring side chain structures and compositions thereof |
16 |
6,509,370 |
|
Paclitaxel
formulation |
17 |
6,509,316 |
|
Pharmaceutical
compositions, methods, and kits for treatment and diagnosis of
lung cancer |
18 |
6,506,910 |
|
Process
for preparing discodermolide and analogues thereof |
19 |
6,506,905 |
|
Method
of preparation of paclitaxel (taxol) using 3-(alk-2-ynyloxy)
carbonyl-5-oxazolidine carboxylic acid |
20 |
6,506,799 |
|
Methods
of treating cardiovascular diseases, dyslipidemia,
dyslipoproteinemia, and hypertension with ether compounds |
21 |
6,506,798 |
|
4-Arylamino,
4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as
selective MEK inhibitors |
22 |
6,506,783 |
|
Cancer
treatments and pharmaceutical compositions therefor |
23 |
6,506,437 |
|
Methods
of coating an implantable device having depots formed in a surface
thereof |
24 |
6,506,411 |
|
Anti-angiogenic
compositions and methods of use |
25 |
6,506,408 |
|
Implantable
or insertable therapeutic agent delivery device |
26 |
6,506,405 |
|
Methods
and formulations of cremophor-free taxanes |
27 |
6,506,399 |
|
Biodegradable
botulinum toxin implant |
28 |
6,503,954 |
|
Biocompatible
carrier containing actinomycin D and a method of forming the same |
29 |
6,503,893 |
|
Method
of treating hyperproliferative diseases using active vitamin D
analogues |
30 |
6,503,556 |
|
Methods
of forming a coating for a prosthesis |
31 |
6,503,481 |
|
Compositions
for aerosolization and inhalation |
32 |
6,503,396 |
|
Method
and apparatus for preparing taxol using supercritical fluid from
source materials |
33 |
6,503,184 |
|
Human
tumor necrosis factor receptor-like proteins TR11, TR11SV1 and
TR11SV2 |
34 |
6,500,966 |
|
Process
for the preparation of taxanes from 10-deacetylbaccatin III |
35 |
6,500,868 |
|
Method
for preventing and treating peripheral neuropathy by administering
selegiline |
36 |
6,500,858 |
|
Taxoid
anti-tumor agents and pharmaceutical compositions thereof |
37 |
6,500,853 |
|
Inhibitors
of phospholipase enzymes |
38 |
6,500,461 |
|
Particulate
formulations |
39 |
6,500,431 |
|
Inhibitors
of angiogenesis and tumor growth |
40 |
6,500,405 |
|
Use
of certain amides as probes for detection of antitubulin activity
and resistance monitoring |
41 |
6,498,945 |
|
Sonodynamic
therapy using an ultrasound sensitizer compound |
42 |
6,498,257 |
|
2,3-olefinic
epothilone derivatives |
43 |
6,498,195 |
|
Use
of
1-propanone-1-(2,4-dihydroxyphenyl)-3-hydroxy-3-(4'-hydroxyphenyl)
as an anticarcinogenic agent |
44 |
6,498,188 |
|
Methods
of treatment for cancer or viral infections |
45 |
6,497,904 |
|
Treatment
of oncologic tumors with an injectable formulation of a golgi
apparatus disturbing agent |
46 |
6,495,719 |
|
Histone
deacetylase inhibitors |
47 |
6,495,705 |
|
Efficient
process for the production of 10-DAB III by selective
hydrazinolysis of various taxanes |
48 |
6,495,663 |
|
Method
and composition for enhancing transport across biological
membranes |
49 |
6,495,659 |
|
Sterically
hindered poly(ethylene glycol) alkanoic acids and derivatives
thereof |
50 |
6,495,600 |
|
Method
and composition for selectively inhibiting melanoma |
51 |
6,495,594 |
|
Biologically
active analogs of discodermolide |
52 |
6,495,579 |
|
Method
for treating multiple sclerosis |
53 |
6,495,571 |
|
Pyridine
compounds, use and preparation thereof |
54 |
6,495,553 |
|
Methods
and compositions for overcoming resistance to biologic and
chemotherapy |
55 |
6,495,520 |
|
Apoptosis
Inducing Molecule II and methods of use |
56 |
6,495,161 |
|
Cytoprotective
biocompatible containment systems for biologically active materials
and methods of making same |
57 |
6,495,129 |
|
Methods
of inhibiting hematopoietic stem cells using human myeloid
progenitor inhibitory factor-1 (MPIF-1) (Ckbeta-8/MIP-3) |
58 |
6,494,862 |
|
Substance
delivery apparatus and a method of delivering a therapeutic
substance to an anatomical passageway |
59 |
6,492,547 |
|
Carboxylic
acid amides, pharmaceutical compositions containing these compounds,
their use and the preparation thereof |
60 |
6,492,379 |
|
Compositions
and formulations of 9-nitrocamptothecin polymorphs and methods of
use therefor |
61 |
6,491,938 |
|
Therapeutic
inhibitor of vascular smooth muscle cells |
62 |
6,489,447 |
|
Protein
purification |
63 |
6,489,369 |
|
Phosphocholine
surfactants and their use |
64 |
6,489,314 |
|
Epothilone
derivatives and methods for making and using the same |
65 |
6,488,962 |
|
Tablet
shapes to enhance gastric retention of swellable controlled-release
oral dosage forms |
66 |
6,486,204 |
|
Treatment
or prevention of prostate cancer with a COX-2 selective inhibiting
drug |
67 |
6,486,202 |
|
Inhibitors
of isoprenyl transferase |
68 |
6,486,146 |
|
Cancer
accelerants and phase synchronization methods |
69 |
6,485,737 |
|
Biodegradable
terephthalate polyester-poly (phosphonate) compositions, articles
and methods of using the same |
70 |
6,485,514 |
|
Local
delivery of therapeutic agents |
71 |
6,482,932 |
|
Nucleoside
triphosphates and their incorporation into oligonucleotides |
72 |
6,482,860 |
|
Pentafluorobenzenesulfonamides
and analogs |
73 |
6,482,850 |
|
Hydrolysis-promoting
hydrophobic taxane derivatives |
74 |
6,482,843 |
|
Compounds
and methods for use thereof in the treatment of cancer or viral
infections |
75 |
6,482,842 |
|
3-aminopyrazole
inhibitors of cyclin dependent kinases |
76 |
6,482,830 |
|
Compositions
and formulations of 9-nitrocamptothecin polymorphs and methods of
use therefor |
77 |
6,482,802 |
|
Use
of neomycin for treating angiogenesis-related diseases |
78 |
6,482,517 |
|
Coated
particles, methods of making and using |
79 |
6,482,439 |
|
Drug
delivery system exhibiting permeability control |
80 |
6,482,436 |
|
Magnetically
responsive composition |
81 |
6,479,679 |
|
Two-step
conversion of protected taxane ester to paclitaxel |
82 |
6,479,512 |
|
Tyrosine
kinase inhibitors |
83 |
6,479,500 |
|
Agents
for alleviating side effects |
84 |
6,479,499 |
|
2-phenyl-4-quinazolinone
compounds, 2-phenyl-4-alkoxy-quinazoline compounds and their
pharmaceutical compositions |
85 |
6,479,481 |
|
Methods
and compositions for treating primary and secondary tumors of the
central nervous system (CNS) |
86 |
6,479,471 |
|
NAALADase
inhibitors |
87 |
6,479,254 |
|
Apoptosis
inducing molecule II |
88 |
6,479,068 |
|
Therapeutic
nutrient regimen for alleviating mucositis, stomatitis and cachexia
in oncology patients |
89 |
6,479,067 |
|
Methods
for treating ovarian cancer, poly (phosphoester) compositions, and
biodegradable articles for same |
90 |
6,478,776 |
|
Implant
delivery catheter system and methods for its use |
91 |
6,476,242 |
|
2-aroyl-4-acyl
paclitaxel (Taxol) analogs |
92 |
6,476,203 |
|
Safe
pharmaceutical composition for treating and preventing infertility
and increasing immune function |
93 |
6,476,195 |
|
Secreted
protein HNFGF20 |
94 |
6,476,068 |
|
Platinum
derivative pharmaceutical formulations |
95 |
6,476,066 |
|
Anti-first-pass
effect compounds |
96 |
6,475,753 |
|
94
Human Secreted Proteins |
97 |
6,475,516 |
|
Drug
delivery via therapeutic hydrogels |
98 |
6,472,585 |
|
Cardiotrophin-1
defective mouse |
99 |
6,472,541 |
|
Protecting
groups with increased photosensitivities |
100 |
6,472,512 |
|
Keratinocyte
derived interferon |
No. 1
- 100 / 101-200
/ 201 - 300 / 301
- 400 / 401 - 500
/ 501 - 600 / 601
- 700 / 701 - 800
/ 801
- 900 / 901 -939
/
|